Regina A. Mangieri
Sunil Sirohi
Ezequiel Marron Fernandez de Velasco
Seungwoo Kang- 1Division of Pharmacology and Toxicology, College of Pharmacy, The University of Texas at Austin, Austin, TX, United States
- 2Laboratory of Endocrine and Neuropsychiatric Disorders, Division of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA, United States
- 3Department of Pharmacology, University of Minnesota, Minneapolis, MN, United States
- 4Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, GA, United States
Editorial on the Research Topic
Advances in pharmacotherapy for alcohol use disorder: from mechanisms to clinical interventions
To overcome alcohol use disorder (AUD), current therapeutic strategies encompass behavioral, psychosocial, and medication-based approaches designed to reduce alcohol use and the associated comorbidities. However, current approved treatments fail many patients, which points to the unmet need to understand mechanisms underlying AUD and develop novel therapeutic targets addressing this disorder’s complex neurobiological foundations. This research collection on this topic aims to provide new information about brain adaptation mechanisms, molecular targets affected by alcohol exposure, pharmacological interventions for alcohol intake, and assessments of strategies for developing practically effective medications for AUD. The findings collectively illustrate diverse avenues for improving the outcomes of AUD interventions.
Pathophysiological adaptation in the striatum has been recognized as a principal brain dysfunction resulting from chronic alcohol exposure, specifically contributing to maladaptive reward-seeking behaviors (Corbit and Janak, 2016). Given the different roles of striatal subregions in shaping reward-seeking patterns and motivation, the detailed characterization of striatal adaptations to chronic alcohol consumption is important to understand the progression from voluntary to inflexible alcohol-seeking behaviors. Recent research by Duffus et al. employed mass spectrometry analysis of protein abundance in the dorsomedial, dorsolateral, and nucleus accumbens subregions of the striatum, at two different abstinence time points following chronic, voluntary alcohol drinking in male and female mice (Duffus et al.). Their comprehensive proteomics data illuminated brain adaptations, such as changes in neurodegeneration-associated proteins, that differed as a function of abstinence duration, subregion, and sex. A general feature, however, was that chronic alcohol drinking appeared to primarily alter proteins important for neuronal structure and cellular health, rather than induce neuroinflammation in the striatum; proteomic profiling revealed changes in proteins and pathways associated with metabolic, cellular organization, protein translation, and molecular transport processes. These findings are in contrast to the literature linking alcohol dependence to upregulation of neuroinflammatory processes, suggesting that the role of neuroinflammation in alcohol-related behavioral changes may vary across different brain regions. On the other hand, it is not clear whether the chronic drinking model employed induces alcohol dependence, and discrepancies with prior work could also be related to differences in the degree of alcohol exposure or the abstinence time point at which proteins were measured. Nonetheless, this work not only demonstrates the importance of subregion-specific characterization but also provides a new list of proteins that establishes a foundation for future investigations of alcohol-induced changes to striatal neuronal structure and cellular health and their behavioral consequences.
Semaglutide, a long-acting analogue of glucagon-like peptide-1, has emerged as an effective weight-loss treatment through appetite regulation in both diabetic and non-diabetic individuals. Accumulative evidence indicates its efficacy in weight loss-independent actions as well (Drucker, 2024). GLP-1 receptor agonists also have recently shown their potential as treatments for AUD in rodent and nonhuman primate studies, and clinical trials to evaluate the efficacy of the agonists have been initiated for AUD patients (Marty et al., 2020; Farokhnia et al., 2025; Hendershot et al., 2025). Aranas et al. examined, using rodent models in both male and female, the potential synergistic effects of combining semaglutide with the well-known anti-smoking agents, varenicline or bupropion, in the reduction of alcohol intake, while simultaneously assessing the impact of a high-fat diet (HFD) (Aranas et al.). Aranas et al. confirmed that semaglutide as a monotherapy effectively reduced alcohol intake and preference. Notably, when semaglutide was combined with either of varenicline, bupropion or HFD, it did not change the effects of semaglutide on the reduction of alcohol intake, suggesting that pharmacological interventions to target GLP-1 provide sufficient effects for AUD without requiring “complex combination regimens”, offering the potential for optimizing treatments for both AUD and obesity. Interestingly, HFD feeding in this study (Aranas et al.) was also found to be equally effective in reducing alcohol drinking, which is consistent with several rodent studies. Considering the nutritional deficiencies following prolonged chronic alcohol consumption and increased intake of palatable food in recovering patients, these data may have important clinical implications in the management of AUD. While a complex relationship between nutrition and AUD exists, the possibility of utilizing a non-pharmacological nutritional intervention that could facilitate the pathway of recovery needs further investigation (White and Sirohi, 2024).
Treatment availability for AUD continues to be limited, evident as less than 10% of patients obtain any form of treatment, and even the treatment rates vary around the world (Venegas et al., 2021). This gap in treatment has prompted exploration of alternative medications, particularly in regions where traditional practices are culturally relevant and accepted. For example, AUD and its comorbidities pose significant public health challenges in Africa, where traditional medicines are also suggested as a complementary and alternative option due to the limited availability of conventional medications. Maling et al. investigated the use of medicinal plants for treating AUD and its comorbidities by Traditional Medicine Practitioners (TMPs) in southwestern Uganda (Maling et al.). Using a descriptive cross-sectional ethnopharmacological survey, they documented diverse plant species employed by TMPs in the Bushenyi district for AUD treatment. While Maling et al. acknowledged potential bias from practitioners withholding sensitive plant information, this study indicates a significant level of agreement among TMPs regarding the use of the identified medicinal plants. Thus, this research serves dual purposes: highlighting the substantial gap in available treatments for AUD in Uganda while demonstrating valuable contribution of traditional medicine to addressing these conditions in Uganda. This provides important information about the use of culturally appropriate treatment approaches that could complement conventional therapies in resource-limited settings.
This research topic also covers an overview of potential therapeutic targets for AUD medications. Fishler et al. reviewed emerging pharmacological treatments for AUD (Fischler et al.), focusing on off-label medications including anticonvulsants, antipsychotics, antidepressants, and neuropeptides. Their analysis highlighted promising results for medications like topiramate, ondansetron, varenicline, neuropeptide Y, oxytocin, ghrelin inverse agonist, and gamma-hydroxybutyrate (GHB), while emphasizing that therapeutic standard implementation requires careful monitoring through comprehensive clinical trials. The review stressed that the comorbidity-reduction strategies would complement traditional treatments focusing on abstinence. It also emphasized that pharmacogenetic approaches may enhance treatment options and improve outcomes for AUD patients, potentially leading to optimized therapeutic effectiveness by enabling personalized medicine approaches.
In sum, this research topic aims to not only deepen our comprehension of AUD’s complex mechanisms but also provide updated information for advanced pharmacotherapeutic developments, providing additional help for individuals confronting this challenging condition. The neurobiological research suggests that alcohol elicits complex effects on proteomic profiles that vary across brain regions. This understanding opens new therapeutic targets focused on cellular organization and protein synthesis pathways. Pharmacological advances, particularly GLP-1 receptor agonists, and additional insights on possible nutritional interventions, such as HFD, offer promising prospects for expanding AUD treatment options. The documentation of traditional medicine practices also importantly contributes to our understanding of culturally accepted traditional treatment approaches that could be integrated with modern medical interventions. Future investigations should focus on translating this information into clinically viable treatments while maintaining awareness of practically available options that affect worldwide treatment implementation.
Author contributions
RM: Writing – original draft, Writing – review and editing. SS: Writing – original draft, Writing – review and editing. EM: Writing – original draft, Writing – review and editing. SK: Writing – original draft, Writing – review and editing.
Funding
The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by the National Institutes of Health (AA030256, AA016651, MH104603 to RAM, 5SC3GM127173-04 to SS, and AA027773, MH137204 to SK).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Corbit, L. H., and Janak, P. H. (2016). Habitual alcohol seeking: neural Bases and possible relations to alcohol Use disorders. Alcohol Clin. Exp. Res. 40, 1380–1389. doi:10.1111/acer.13094
Drucker, D. J. (2024). The benefits of GLP-1 drugs beyond obesity. Science 385, 258–260. doi:10.1126/science.adn4128
Farokhnia, M., Tazare, J., Pince, C. L., Bruns, N. T., Gray, J. C., Lo Re, V., et al. (2025). Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake. J. Clin. Invest. 135, e188314. doi:10.1172/JCI188314
Hendershot, C. S., Bremmer, M. P., Paladino, M. B., Kostantinis, G., Gilmore, T. A., Sullivan, N. R., et al. (2025). Once-weekly semaglutide in adults with alcohol Use disorder: a randomized clinical trial. JAMA Psychiatry 82, 395–405. doi:10.1001/jamapsychiatry.2024.4789
Marty, V. N., Farokhnia, M., Munier, J. J., Mulpuri, Y., Leggio, L., and Spigelman, I. (2020). Long-acting glucagon-like peptide-1 receptor agonists suppress voluntary alcohol intake in male Wistar rats. Front. Neurosci. 14, 599646. doi:10.3389/fnins.2020.599646
Venegas, A., Donato, S., Meredith, L. R., and Ray, L. A. (2021). Understanding low treatment seeking rates for alcohol use disorder: a narrative review of the literature and opportunities for improvement. Am. J. Drug Alcohol Abuse 47, 664–679. doi:10.1080/00952990.2021.1969658
Keywords: alcohol use disorder (AUD), striatum, GLP-1, glucagon-like peptide-1, high fat diet (HFD), pharmacotherapeutics, traditional medicine
Citation: Mangieri RA, Sirohi S, Marron Fernandez de Velasco E and Kang S (2025) Editorial: Advances in pharmacotherapy for alcohol use disorder: from mechanisms to clinical interventions. Front. Pharmacol. 16:1671114. doi: 10.3389/fphar.2025.1671114
Received: 22 July 2025; Accepted: 06 August 2025;
Published: 15 August 2025.
Edited and reviewed by:
Venkateshwar G. Keshamouni, University of Michigan, United StatesCopyright © 2025 Mangieri, Sirohi, Marron Fernandez de Velasco and Kang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Seungwoo Kang, c2VrYW5nQGF1Z3VzdGEuZWR1